چاپ صفحه |  صفحه نخست سامانه |  نویسندگان |  اطلاعات تفضیلی |  دانلود مقاله | دانشگاه علوم پزشکی تبریز |
| نویسنده ثبت کننده مقاله | رعنا جهانبان اسفهلان |
| مرحله جاری مقاله | تایید نهایی |
| دانشکده/مرکز مربوطه | دانشکده علوم نوین پزشکی |
| کد مقاله | 64506 |
| عنوان فارسی مقاله | NOVEL DOX-MTX NANOPARTICLES IMPROVE ORAL SCC CLINICAL OUTCOME BY DOWN REGULATION OF LYMPH DISSEMINATION FACTOR VEGF-C EXPRESSION IN VIVO: ORAL AND IV MODALITIES |
| عنوان لاتین مقاله | NOVEL DOX-MTX NANOPARTICLES IMPROVE ORAL SCC CLINICAL OUTCOME BY DOWN REGULATION OF LYMPH DISSEMINATION FACTOR VEGF-C EXPRESSION IN VIVO: ORAL AND IV MODALITIES |
| نوع ارائه | سخنرانی |
| عنوان کنگره / همایش | International Conference of Current Cancer Medicine (I4CM) |
| نوع کنگره / همایش | بین المللی |
| کشور محل برگزاری کنگره/ همایش | Poland |
| شهر محل برگزاری کنگره/ همایش | warsaw |
| سال انتشار/ ارائه شمسی | 1396 |
| سال انتشار/ارائه میلادی | 2017 |
| تاریخ شمسی شروع و خاتمه کنگره/همایش | 1396/06/16 الی 1396/06/16 |
| آدرس لینک مقاله/ همایش در شبکه اینترنت | http://i4cm.net/novel-dox-mtx-nanoparticles-improve-oral-scc-clinical-outcome-by-down-regulation-of-lymph-dissemination-factor-v |
| آدرس علمی (Affiliation) نویسنده متقاضی | Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran |
| نویسنده | نفر چندم مقاله |
|---|---|
| خالد صیدی | اول |
| رعنا جهانبان اسفهلان | دوم |
| علی جهانبان اسفهلان | سوم |
| مهران مسگری عباسی | پنجم |
| عنوان | متن |
|---|---|
| کلمات کلیدی | VEGF-C - DOX-MTX-NPs - oral squamous cell carcinoma (OSCC) - oral and IV modalities |
| خلاصه مقاله | Purpose: Oral squamous cell carcinoma (OSCC) remains as one of the most difficult malignancies to control because of its high propensity for local invasion and cervical lymph node dissemination. The aim of present study was to evaluate the efficacy of novel pH and temperature sensitive doxorubicin-methotrexateloaded nanoparticles (DOX-MTX NP) in terms of their potential to change the VEGF-C expression profile in a rat OSCC model. Materials and methods: 120 male rats were divided into 8 groups of 15 animals administrated with 4-nitroquinoline-1-oxide to induce OSCCs. Newly formulated doxorubicin-methotrexate-loaded nanoparticles (DOX-MTX NP) and free doxorubicin were IV and orally administered. Results: Our results indicated that both oral and IV forms of DOX-MTX- nanoparticle complexes caused significant decrease in the mRNA level of VEGF-C compared to untreated cancerous rats (p0.05). Furthermore, in DOX-MTX NP treated group, less tumors characterized with advanced stage and VEGF-C mRNA level paralleled with improved clinical outcome (p0.05). Conclusions: VEGF-C is one of the main prognosticators for lymph node metastasis in OSCC. Down-regulation of this lymph-angiogenesis promoting factor is a new feature acquired in group treated with dual action DOX-MTX-NPs. Beside the synergic apoptotic properties of concomitant use of DOX and MTX on OSCC, DOX-MTX NPs possessed anti-angiogenesis properties which was related to the improved clinical outcome in treated rats. Conclusion: Taking together, we conclude that our multifunctional doxorubicin-methotrexate complex exerts specific potent apoptotic and anti-angiogenesis properties that could ameliorate the clinical outcome presumably via down-regulating dissemination factor-VEGF-C expression in a rat OSCC model. |
| نام فایل | تاریخ درج فایل | اندازه فایل | دانلود |
|---|---|---|---|
| img115.pdf | 1397/08/11 | 292695 | دانلود |
| (13) VEGF NPS.pdf | 1397/08/11 | 681333 | دانلود |
